Alberta-Wide Funding Opportunity

 

The Alberta Diabetes Institute at the University of Alberta is pleased to announce a collaboration with Janssen Pharmaceuticals and its parent company Johnson & Johnson to advance early-stage technologies related to Type I and Type II diabetes.  The Alberta Diabetes Institute - Johnson & Johnson Diabetes Research Fund is a $600,000 partnership between Alberta Diabetes Foundation, Janssen Inc. (Johnson & Johnson) and the Government of Alberta.  The three year competitive fund, administered by U of A’s Alberta Diabetes Institute, will support research in either Type I or Type II diabetes with a focus on highly novel hypothesis-testing for targets, agents, therapies, diagnostics, etc., discovery research with a high potential for commercialization.

This is the second year of funding and this year's Letter of Intent is due April 2, 2015.  The LOI's will be evaluated by a review committee that includes industry representation. This will be followed by invitation for full application.  Up to a maximum of $50,000 for one year may be requested and we will fund up to 4 applicants.

 

IMPORTANT DATES:

• April 2, 2015 = LOI due
• May 29, 2015 = Invitations for full application
• June 30, 2015 = Full applications due
• July 31, 2015 = Award announcements.

For more information regarding the funding opportunity visit http://www.adi.ualberta.ca/ResearchFund.aspx.